US Archives - Page 34 of 79 - European Medical Journal

L.A. Wildfires Worsen Respiratory Risks

Los Angeles healthcare professionals face a growing crisis as wildfire smoke engulfs the region, posing severe health risks for millions.

Doxycycline Postexposure Prophylaxis Shows Major Impact in STI Prevention

A new cohort study reveals that doxycycline postexposure prophylaxis (DoxyPEP) significantly reduces rates of bacterial sexually transmitted infections (STIs) among individuals using HIV preexposure prophylaxis (PrEP).

Revolutionizing REM Sleep Disorder Diagnosis With AI

A new, cost-effective method for diagnosing isolated REM sleep behavior disorder (iRBD) using 2D cameras and advanced computer vision algorithms has been explored in a new study.

Advancing Precision Immunotherapy for Stage II Melanoma

A recent study has uncovered promising advancements in the fight against Stage II melanoma by introducing a novel biomarker technique, immune Förster resonance energy transfer (iFRET).

Medication-Free Remission in Juvenile Dermatomyositis

Achieving medication-free remission (MFR) is a critical milestone in the treatment of juvenile dermatomyositis (JDM), a rare inflammatory disease primarily affecting skin and muscles.

Investigation Into the Long-Term Clinical Outcomes of EVT

A newly published systematic review and meta-analysis underscores the enduring benefits of endovascular thrombectomy (EVT) for patients with acute ischemic stroke caused by large vessel occlusion.

Breakthrough in Relapsed DLBCL Treatment

A Phase III clinical trial, ECHELON-3, has demonstrated survival benefits for patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) using a combination therapy of brentuximab vedotin (BV), lenalidomide (Len), and rituximab (R).

Canadian Wildfires Increase Lung Risks in Eastern US

The growing health crisis posed by wildfire smoke, even from thousands of miles away, was made clear in a recently published study.

UV Radiation and Merkel Cell Cancer Risk

An epidemiological study has shed light on the primary risk factors driving Merkel cell carcinoma (MCC), a rare but aggressive form of skin cancer.

Exploring Botulinum Toxin for Raynaud’s Treatment

Botulinum toxin (BTX), widely known for its cosmetic and neurological applications, is emerging as a potential treatment for Raynaud’s phenomenon (RP), particularly when secondary to scleroderma.